Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Cash Flows (Unaudited)

v3.21.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Cash flows from operating activities:    
Net loss $ (4,904,196) $ (4,738,346)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 201,593 217,650
Stock-based compensation 384,407 97,308
Non-cash interest expense 46,488 35,902
Change in fair value of preferred stock warrant liability 170,456
Non-cash portion of loss on debt extinguishment 160,895
Deferred rent 42,658 172,268
Changes in operating assets and liabilities:    
Accounts receivable (1,187,954) (364,702)
Prepaid expenses and other current assets 18,883 (27,951)
Accounts payable 783,415 (31,770)
Accrued expenses and other current liabilities (782,118) (848,406)
Deferred revenue (63,986) (300,783)
Net cash used in operating activities (5,299,915) (5,618,374)
Cash flows from investing activities:    
Purchase of property and equipment (157,346) (256,517)
Net cash used in investing activities (157,346) (256,517)
Cash flows from financing activities:    
Proceeds from loan 15,000,000
Payment to unaccredited investors of Augmedix Operating Corporation (21,171)
Repayment of notes payable (12,965,829)
Proceeds from issuance of convertible notes payable 499,999
Payment of financing costs (195,000) (4,017)
Proceeds from exercise of common stock warrants 3,619
Proceeds from exercise of stock options 1,646
Net cash provided by financing activities 1,821,619 497,628
Effect of exchange rate changes on cash and restricted cash (403) (2,832)
Net decrease in cash and restricted cash (3,636,045) (5,380,095)
Cash and restricted cash at beginning of period 22,972,986 11,603,385
Cash and restricted cash at end of period 19,336,941 6,223,290
Supplemental disclosure of cash flow information:    
Cash paid during the period for interest 392,611 320,785
Supplemental schedule of non-cash investing and financing activities:    
Fair value of warrants issued in connection with loan 395,412
Financing costs in accrued expenses $ 37,199